Development of venetoclax performance using its new derivatives on BCL-2 protein inhibition

Area of Science:

• Oncology
• Molecular Biology
• Computational Chemistry

Background:

• Cancer cells evade apoptosis, a key hallmark of cancer.
• The BCL-2 protein family regulates apoptosis and is a target for cancer therapy.
• Venetoclax (VNT) is an existing BCL-2 inhibitor.

Purpose of the Study:

• To design novel analogs of venetoclax (VNT) with improved anticancer properties.
• To enhance the inhibition of BCL-2 protein for increased cancer cell death.

Main Methods:

• Molecular docking studies were employed to predict binding energies of VNT and its derivatives.
• Molecular dynamics simulations were used to assess the inhibitory effects on BCL-2 protein.

Main Results:

• The VNT-12 analog exhibited the lowest binding free energy (-12.15 kcal/mol) among the designed compounds.
• Molecular dynamics simulations indicated that VNT-12 demonstrated enhanced inhibition of BCL-2 protein compared to VNT.

Conclusions:

• The novel VNT-12 analog shows significant potential as an improved inhibitor of BCL-2.
• This study highlights the efficacy of computational approaches in designing potent anticancer agents.